|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lowe KA, Chia VM, Taylor A, O'Malley C,
Kelsh M, Mohamed M, Mowat FS and Goff B: An international
assessment of ovarian cancer incidence and mortality. Gynecol
Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin
MC, You SL, Cheng WF and Lai MS: Trends in incidence and survival
outcome of epithelial ovarian cancer: 30-year national
population-based registry in Taiwan. J Gynecol Oncol. 24:342–351.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang B, Liu SZ, Zheng RS, Zhang F, Chen WQ
and Sun XB: Time Trends of Ovarian Cancer Incidence in China. Asian
Pac J Cancer Prev. 15:191–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lawrie TA, Bryant A, Cameron A, Gray E and
Morrison J: Pegylated liposomal doxorubicin for relapsed epithelial
ovarian cancer. Cochrane Database Syst Rev: CD006910. 2013.
View Article : Google Scholar
|
|
6
|
Gadducci A, Cosio S, Zola P, Landoni F,
Maggino T and Sartori E: Surveillance procedures for patients
treated for epithelial ovarian cancer: A review of the literature.
Int J Gynecol Cancer. 17:21–31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams SV, Quraishi SM, Shafer MM,
Passarelli MN, Freney EP, Chlebowski RT, Luo J, Meliker JR, Mu L,
Neuhouser ML and Newcomb PA: Dietary cadmium exposure and risk of
breast, endometrial and ovarian cancer in the Women's Health
Initiative. Environ Health Perspect. 122:594–600. 2014.PubMed/NCBI
|
|
8
|
Schock H, Surcel HM, Zeleniuch-Jacquotte
A, Grankvist K, Lakso HÅ, Fortner RT, Kaaks R, Pukkala E, Lehtinen
M, Toniolo P and Lundin E: Early pregnancy sex steroids and
maternal risk of epithelial ovarian cancer. Endocr Relat Cancer.
21:831–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi
T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S and Kobayashi H:
Molecular genetics and epidemiology of epithelial ovarian cancer.
Oncol Rep. 26:1347–1356. 2011.PubMed/NCBI
|
|
10
|
Costa FF: Non-coding RNAs, epigenetics and
complexity. Gene. 410:9–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taft RJ, Pang KC, Mercer TR, Dinger M and
Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol.
220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hung T and Chang HY: Long noncoding RNA in
genome regulation: Prospects and mechanisms. RNA Biol. 7:582–585.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bonasio R and Shiekhattar R: Regulation of
transcription by long noncoding RNAs. Annu Rev Genet. 48:433–455.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haemmerle M and Gutschner T: Long
non-coding RNAs in cancer and development: Where do we go from
here? Int J Mol Sci. 16:1395–1405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunej T, Obsteter J, Pogacar Z, Horvat S
and Calin GA: The decalog of long non-coding RNA involvement in
cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 51:344–357.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zuo C, Wang Z, Lu H, Dai Z, Liu X and Cui
L: Expression profiling of lncRNAs in C3H10T1/2 mesenchymal stem
cells undergoing early osteoblast differentiation. Mol Med Rep.
8:463–467. 2013.PubMed/NCBI
|
|
17
|
Li J, Long W, Li Q, Zhou Q, Wang Y, Wang
H, Zhou B and Li J: Distinct expression profiles of lncRNAs between
regressive and mature scars. Cell Physiol Biochem. 35:663–675.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanehisa M: Molecular network analysis of
diseases and drugs in KEGG. Methods Mol Biol. 939:263–275. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu S, Li G, Zhang X, Yan J, Gao J, An X,
Liu Y and Su P: Aberrant expression of long noncoding RNAs in
chronic thromboembolic pulmonary hypertension. Mol Med Rep.
11:2631–2643. 2015.PubMed/NCBI
|
|
21
|
Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao
T, Liu Y, Ou J, Wang D, Yao L, et al: LncRNA-HOST2 regulates cell
biological behaviors in epithelial ovarian cancer through a
mechanism involving microRNA let-7b. Hum Mol Genet. 24:841–852.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Medrzycki M, Zhang Y, Zhang W, Cao K, Pan
C, Lailler N, McDonald JF, Bouhassira EE and Fan Y: Histone h1.3
suppresses h19 noncoding RNA expression and cell growth of ovarian
cancer cells. Cancer Res. 74:6463–6473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rinn JL, Kertesz M, Wang JK, Squazzo SL,
Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and
Chang HY: Functional demarcation of active and silent chromatin
domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW,
Jin HY, Zhang Y, Li Q and Hua KQ: Overexpression of long non-coding
RNA HOTAIR predicts poor patient prognosis and promotes tumor
metastasis in epithelial ovarian cancer. Gynecol Oncol.
134:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miyoshi N, Wagatsuma H, Wakana S,
Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino
T and Ishino F: Identification of an imprinted gene, Meg3/Gtl2 and
its human homologue MEG3, first mapped on mouse distal chromosome
12 and human chromosome 14q. Genes Cells. 5:211–220. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Zhou Y, Mehta KR, Danila DC,
Scolavino S, Johnson SR and Klibanski A: A pituitary-derived MEG3
isoform functions as a growth suppressor in tumor cells. J Clin
Endocrinol Metab. 88:5119–5126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huarte M, Guttman M, Feldser D, Garber M,
Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M,
et al: A large intergenic noncoding RNA induced by p53 mediates
global gene repression in the p53 response. Cell. 142:409–419.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheng X and Li J, Yang L, Chen Z, Zhao Q,
Tan L, Zhou Y and Li J: Promoter hypermethylation influences the
suppressive role of maternally expressed 3, a long non-coding RNA,
in the development of epithelial ovarian cancer. Oncol Rep.
32:277–285. 2014.PubMed/NCBI
|
|
29
|
Schneider C, King RM and Philipson L:
Genes specifically expressed at growth arrest of mammalian cells.
Cell. 54:787–793. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao S, Liu W, Li F, Zhao W and Qin C:
Decreased expression of lncRNA GAS5 predicts a poor prognosis in
cervical cancer. Int J Clin Exp Pathol. 7:6776–6783.
2014.PubMed/NCBI
|
|
31
|
Shi X, Sun M, Liu H, Yao Y, Kong R, Chen F
and Song Y: A critical role for the long non-coding RNA GAS5 in
proliferation and apoptosis in non-small-cell lung cancer. Mol
Carcinog. 54:E1–E12. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Melhem A, Yamada SD, Fleming GF, Delgado
B, Brickley DR, Wu W, Kocherginsky M and Conzen SD: Administration
of glucocorticoids to ovarian cancer patients is associated with
expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in
ovarian tissues. Clin Cancer Res. 15:3196–3204. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dickinson RE, Fegan KS, Ren X, Hillier SG
and Duncan WC: Glucocorticoid regulation of SLIT/ROBO tumour
suppressor genes in the ovarian surface epithelium and ovarian
cancer cells. PLoS One. 6:e277922011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu MJ, Fang GE, Liu YJ and Song LN:
Effects of glucocorticoid on proliferation, differentiation and
glucocorticoid receptor expression in human ovarian carcinoma cell
line 3AO. Acta Pharmacol Sin. 23:819–823. 2002.PubMed/NCBI
|
|
35
|
Kino T, Hurt DE, Ichijo T, Nader N and
Chrousos GP: Noncoding RNA gas5 is a growth arrest- and
starvation-associated repressor of the glucocorticoid receptor. Sci
Signal. 3:ra82010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Beauchamp MC, Yasmeen A, Knafo A and
Gotlieb WH: Targeting insulin and insulin-like growth factor
pathways in epithelial ovarian cancer. J Oncol. 2010:2570582010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dadmarz RD, Ordoubadi A, Mixon A, Thompson
CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA and
Schwartzentruber DJ: Tumor-infiltrating lymphocytes from human
ovarian cancer patients recognize autologous tumor in an MHC class
II-restricted fashion. Cancer J Sci Am. 2:263–272. 1996.PubMed/NCBI
|
|
38
|
Beesley J, Jordan SJ, Spurdle AB, Song H,
Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, McGuire V, Whittemore
AS, et al: Association between single-nucleotide polymorphisms in
hormone metabolism and DNA repair genes and epithelial ovarian
cancer: results from two Australian studies and an additional
validation set. Cancer Epidemiol Biomarkers Prev. 16:2557–2565.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mei FC, Young TW, Liu J and Cheng X:
RAS-mediated epigenetic inactivation of OPCML in oncogenic
transformation of human ovarian surface epithelial cells. FASEB J.
20:497–499. 2006.PubMed/NCBI
|
|
40
|
Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M
and Tian Y: Downregulation of HNF1 homeobox B is associated with
drug resistance in ovarian cancer. Oncol Rep. 32:979–988.
2014.PubMed/NCBI
|
|
41
|
Ji M, Shi H, Xie Y, Zhao Z, Li S, Chang C,
Cheng X and Li Y: Ubiquitin specific protease 22 promotes cell
proliferation and tumor growth of epithelial ovarian cancer through
synergy with transforming growth factor β1. Oncol Rep. 33:133–140.
2015.PubMed/NCBI
|
